Hormonal
SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone demonstrate benefits across multiple cardiometabolic conditions, improving clinical outcomes in patients with MASLD, CKD, and CVD.
Current medications like SGLT2 inhibitors, GLP-1 agonists, and finerenone are effective for treating multiple aspects of cardiometabolic disease simultaneously. Discuss these options with your doctor if you have liver, kidney, or heart issues.
new medications such as sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), combined gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists, and finerenone have demonstrated benefits across multiple conditions in this spectrum, improving both quality of life and hard clinical outcomes
Why this rating
The paper cites references [3,4] for the benefits, implying established clinical trial data, though specific trial names are not detailed in the text.
Source
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis et al. · Biomolecules · 2025
DOI 10.3390/biom15020213
More from this paper
- Excess adiposity, particularly visceral fat, is the central driver of the Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome, leading to insulin resistance, inflammation, and multi-organ dysfunction.Strong
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is bidirectionally associated with the development and progression of cardiovascular, renal, and metabolic disorders, acting as both a driver and consequence of systemic cardiometabolic dysfunction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →